Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report

European Society for Blood and Marrow Transplantation (EBMT)

Research output: Contribution to journalArticle

Abstract

Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the hematopoietic system. In 2016, there was a tendency for continued activity in this field with 43,636 HCT in 39,313 patients [16,507 allogeneic (42%), 22,806 autologous (58%)] reported by 679 centers in 49 countries in 2016. The main indications were myeloid malignancies 9547 (24%; 96% allogeneic), lymphoid malignancies 25,618 (65%; 20% allogeneic), solid tumors 1516 (4%; 2% allogeneic), and non-malignant disorders 2459 (6%; 85% allogeneic). There was a remarkable leveling off in the use of unrelated donor HCT being replaced by haploidentical HCT. Continued growth in allogeneic HCT for marrow failure, AML, and MPN was seen, whereas MDS appears stable. Allogeneic HCT for lymphoid malignancies vary in trend with increases for NHL and decreases for Hodgkin lymphoma and myeloma. Trends in CLL are not clear, with recent increases after a decrease in activity. In autologous HCT, the use in myeloma continues to expand but is stable in Hodgkin lymphoma. There is a notable increase in autologous HCT for autoimmune disease. These data reflect the most recent advances in the field, in which some trends and changes are likely to be related to development of non-transplant technologies.

Original languageEnglish
Pages (from-to)1139-1148
Number of pages10
JournalBone Marrow Transplantation
Volume53
Issue number9
DOIs
Publication statusPublished - Sep 2018

Fingerprint

Unrelated Donors
Cell Transplantation
Transplantation
Bone Marrow
Transplants
Hodgkin Disease
Neoplasms
Hematopoietic System
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Surveys and Questionnaires
Autoimmune Diseases
Technology
Growth

Cite this

Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. / European Society for Blood and Marrow Transplantation (EBMT).

In: Bone Marrow Transplantation, Vol. 53, No. 9, 09.2018, p. 1139-1148.

Research output: Contribution to journalArticle

@article{b6a36d1e27274d4eac9448d8eb0a5878,
title = "Is the use of unrelated donor transplantation leveling off in Europe?: The 2016 European Society for Blood and Marrow Transplant activity survey report",
abstract = "Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the hematopoietic system. In 2016, there was a tendency for continued activity in this field with 43,636 HCT in 39,313 patients [16,507 allogeneic (42{\%}), 22,806 autologous (58{\%})] reported by 679 centers in 49 countries in 2016. The main indications were myeloid malignancies 9547 (24{\%}; 96{\%} allogeneic), lymphoid malignancies 25,618 (65{\%}; 20{\%} allogeneic), solid tumors 1516 (4{\%}; 2{\%} allogeneic), and non-malignant disorders 2459 (6{\%}; 85{\%} allogeneic). There was a remarkable leveling off in the use of unrelated donor HCT being replaced by haploidentical HCT. Continued growth in allogeneic HCT for marrow failure, AML, and MPN was seen, whereas MDS appears stable. Allogeneic HCT for lymphoid malignancies vary in trend with increases for NHL and decreases for Hodgkin lymphoma and myeloma. Trends in CLL are not clear, with recent increases after a decrease in activity. In autologous HCT, the use in myeloma continues to expand but is stable in Hodgkin lymphoma. There is a notable increase in autologous HCT for autoimmune disease. These data reflect the most recent advances in the field, in which some trends and changes are likely to be related to development of non-transplant technologies.",
author = "{European Society for Blood and Marrow Transplantation (EBMT)} and Passweg, {Jakob R} and Helen Baldomero and Peter Bader and Basak, {Grzegorz W} and Chiara Bonini and Rafael Duarte and Carlo Dufour and Nicolaus Kr{\"o}ger and J{\"u}rgen Kuball and Arjan Lankester and Silvia Montoto and Arnon Nagler and Snowden, {John A} and Jan Styczynski and Mohamad Mohty",
year = "2018",
month = "9",
doi = "10.1038/s41409-018-0153-1",
language = "English",
volume = "53",
pages = "1139--1148",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Is the use of unrelated donor transplantation leveling off in Europe?

T2 - The 2016 European Society for Blood and Marrow Transplant activity survey report

AU - European Society for Blood and Marrow Transplantation (EBMT)

AU - Passweg, Jakob R

AU - Baldomero, Helen

AU - Bader, Peter

AU - Basak, Grzegorz W

AU - Bonini, Chiara

AU - Duarte, Rafael

AU - Dufour, Carlo

AU - Kröger, Nicolaus

AU - Kuball, Jürgen

AU - Lankester, Arjan

AU - Montoto, Silvia

AU - Nagler, Arnon

AU - Snowden, John A

AU - Styczynski, Jan

AU - Mohty, Mohamad

PY - 2018/9

Y1 - 2018/9

N2 - Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the hematopoietic system. In 2016, there was a tendency for continued activity in this field with 43,636 HCT in 39,313 patients [16,507 allogeneic (42%), 22,806 autologous (58%)] reported by 679 centers in 49 countries in 2016. The main indications were myeloid malignancies 9547 (24%; 96% allogeneic), lymphoid malignancies 25,618 (65%; 20% allogeneic), solid tumors 1516 (4%; 2% allogeneic), and non-malignant disorders 2459 (6%; 85% allogeneic). There was a remarkable leveling off in the use of unrelated donor HCT being replaced by haploidentical HCT. Continued growth in allogeneic HCT for marrow failure, AML, and MPN was seen, whereas MDS appears stable. Allogeneic HCT for lymphoid malignancies vary in trend with increases for NHL and decreases for Hodgkin lymphoma and myeloma. Trends in CLL are not clear, with recent increases after a decrease in activity. In autologous HCT, the use in myeloma continues to expand but is stable in Hodgkin lymphoma. There is a notable increase in autologous HCT for autoimmune disease. These data reflect the most recent advances in the field, in which some trends and changes are likely to be related to development of non-transplant technologies.

AB - Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the hematopoietic system. In 2016, there was a tendency for continued activity in this field with 43,636 HCT in 39,313 patients [16,507 allogeneic (42%), 22,806 autologous (58%)] reported by 679 centers in 49 countries in 2016. The main indications were myeloid malignancies 9547 (24%; 96% allogeneic), lymphoid malignancies 25,618 (65%; 20% allogeneic), solid tumors 1516 (4%; 2% allogeneic), and non-malignant disorders 2459 (6%; 85% allogeneic). There was a remarkable leveling off in the use of unrelated donor HCT being replaced by haploidentical HCT. Continued growth in allogeneic HCT for marrow failure, AML, and MPN was seen, whereas MDS appears stable. Allogeneic HCT for lymphoid malignancies vary in trend with increases for NHL and decreases for Hodgkin lymphoma and myeloma. Trends in CLL are not clear, with recent increases after a decrease in activity. In autologous HCT, the use in myeloma continues to expand but is stable in Hodgkin lymphoma. There is a notable increase in autologous HCT for autoimmune disease. These data reflect the most recent advances in the field, in which some trends and changes are likely to be related to development of non-transplant technologies.

U2 - 10.1038/s41409-018-0153-1

DO - 10.1038/s41409-018-0153-1

M3 - Article

C2 - 29540849

VL - 53

SP - 1139

EP - 1148

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -